Date: January 07, 2024

To The Manager Corporate Relations Department **BSE** Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001

Dear Sir/Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Sub: Change in Directors or Key Managerial Personnel - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

With reference to the captioned subject, we would like to inform you that the Board of Directors at its Meeting held on Saturday, 06th January 2024, has inter alia, based on the recommendation of Nomination and Remuneration Committee approved the following:

1. Appointment of Dr. Shankarappa Nagaraja Vinaya Babu (DIN: 01373832) as Director and Chairman (Non-Executive & Non-Independent) of the Company subject to the approval of the members of the Company at the ensuing General Meeting of the Company.

The Board has considered and approved the appointment of Dr. Shankarappa Nagaraja Vinaya Babu (DIN: 01373832) as a Director and Chairman (Non-executive & Non-Independent) of the Company, pursuant to recommendation of the Nomination and Remuneration Committee. The matter to be placed before the Shareholders in the ensuing General Meeting for approval.

The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13th 2023, is enclosed as **Annexure I.**

2. Appointment of Dr. Prasad S as Chief Executive Officer (CEO) of the Company in the **Category of Key Managerial Personnel.**

The Board has considered and approved the appointment of Dr. Prasad S as Chief Executive Officer (CEO) of the Company pursuant to recommendation of the Nomination and Remuneration Committee w.e.f. 06th January, 2024.



The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023 is given in **Annexure II.**

Kindly take the same on your record and oblige.

Thanking You

For Pharmaids Pharmaceuticals Limited

Kaushik Kumar

Caute U

(Company Secretary & Head-Legal)



Annexure I

Brief particulars of the Director/KMP proposed for proposed to appointed/ reappointed.

| S. No | Particulars | Details |
|-------|--|---|
| 1 | Reasons for Change viz. | Dr. Shankarappa Nagaraja Vinaya |
| | Appointment /re-appointment , | Babu is appointed as Director and |
| | resignation, removal, death or | Chairman (Non-Executive & Non- |
| | otherwise | Independent) of the Company. |
| 2 | Date of appointment/re- | January 06, 2024 (Subject to approval of |
| | appointment & Term of | shareholders at the ensuing extra ordinary |
| | appointment/ re-appointment | general meeting scheduled to be held on |
| | | 31 st January 2024). |
| | | |
| | | Terms of Appointment: As recommended |
| | | by the Nomination and Remuneration |
| | | Committee and agreed by the Board of |
| | | Directors. |
| 3 | Brief profile | Dr. Shankarappa Nagaraja Vinaya Babu |
| | | holds a bachelor's degree in veterinary |
| | | science from the University of Agricultural |
| | | Sciences, Bangalore. He is the founder and |
| | | managing director of Bioneeds India |
| | | Private Limited, with over 20+ years of |
| | | experience in various segments of pre- |
| | | clinical development. In the past, he has |
| | | been associated with Rallis India Limited, |
| | | Godrej Agrovet Limited, Limited and Aurigene Discovery Technologies |
| | | Aurigene Discovery Technologies Limited. |
| 4 | Disclosure of Relationships | Dr. Shankarappa Nagaraja Vinaya Babu is |
| | between Directors | not related to any Directors or Key |
| | | Managerial Personnel of the Company |

For Pharmaids Pharmaceuticals Limited

Kaushik Kumar

Carle U

(Company Secretary & Head-Legal)



Annexure II

Brief particulars of the Director/KMP proposed for proposed to appointed/reappointed.

| S. No | Particulars | Details |
|-------|--|--|
| 1 | Reasons for Change viz. | Dr. Prasad S is appointed as Chief Executive |
| | Appointment / re- | Officer (CEO) of the Company. |
| | appointment , resignation, | |
| | removal, death or otherwise | |
| 2 | Date of appointment/re- | January 06, 2024. |
| | appointment & Term of | |
| | appointment/ re-appointment | Terms of Appointment: As recommended by |
| | | the Nomination and Remuneration Committee |
| | | and agreed by the Board of Directors. |
| 3 | Brief profile | Dr. Prasad S holds a bachelor's degree in |
| | | veterinary medicine, as well as master's and |
| | | doctoral specializations in Pharmacology and |
| | | Toxicology from UAS and KVAFSU, Bangalore. |
| | | Dr. Prasad S brings over 18 years of extensive expertise in the field of drug discovery and development, specializing in the CRO/CRISP/CRAMS/CDMO business domain. With a proven track record of fostering organizational success through strategic leadership, innovation, and transformative initiatives, he has successfully led projects from conceptualization to market implementation by assembling high-performing scientific teams. His professional journey includes notable roles at Aurigene Discovery Technology Limited, Evolova Biotech Private Limited, Syngene |
| | | International Limited, and Anthem Biosciences |
| | | Private Limited. |

For Pharmaids Pharmaceuticals Limited

Kaushik Kumar

(Company Secretary & Head-Legal)